Patent intelligence · US
US 8884014
Method for purifying a fused pyrrolocarbazole derivative
Method for purifying a fused pyrrolocarbazole derivative
Patent details — US 8884014
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 11, 2014
- Expiration
- Nov 6, 2034
- Applicant
- Teva Sante
- Claims
- 7
- CPC classes
- A61P, A61P35/00
Quick answer
US 8884014 (Method for purifying a fused pyrrolocarbazole derivative) is held by Teva Sante. Status: granted. Granted Nov 11, 2014. Expires Nov 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Teva Sante
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61P, A61P35/00
More from Teva Sante
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 8884014?
US 8884014 (Method for purifying a fused pyrrolocarbazole derivative) is held by Teva Sante. Status: granted. Granted Nov 11, 2014. Expires Nov 6, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8884014?
Teva Sante is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8884014 expire?
Our index shows an expiration date of Nov 6, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.